Elevation Oncology Inc
Change company Symbol lookup
Select an option...
ELEV Elevation Oncology Inc
FRZA Forza X1 Inc
SIEN Sientra Inc
PMGM Priveterra Acquisition Corp
NVFY Nova LifeStyle Inc
GGIFF Garibaldi Resources Corp
MIGI Mawson Infrastructure Group Inc
GTIM Good Times Restaurants Inc
BENF Avalon Acquisition Inc
SOS Sos Ltd
Go

Health Care : Biotechnology |
Company profile

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 (SYSA1801 or CPO102), is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Claudin 18.2 is expressed across several solid tumor types, including many gastrointestinal cancers such as gastric, gastroesophageal junction and pancreatic cancer. Claudin 18.2 is also expressed in ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors. The Company is exploring opportunities through new or existing partnerships and business development opportunities to expand its novel oncology pipeline.

Price
Delayed
$1.73
Day's Change
-1.09 (-38.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.07
Day's Low
1.50
Volume
(Heavy Day)

Today's volume of 5,981,473 shares is on pace to be much greater than ELEV's 10-day average volume of 8,118,558 shares.

5,981,473

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marathon Digital Holdings, Inc. - MARA

4:30 pm ET March 24, 2023 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / March 24, 2023 / Pomerantz LLP is investigating claims on behalf of investors of Marathon Digital Holdings, Inc.("Marathon" or the "Company") (NASDAQ:MARA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Marathon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 28, 2023, Marathon issued a press release "announc[ing] . . . that it has cancelled its webcast and conference call for the fourth quarter and fiscal year 2022, initially scheduled for today, February 28, 2023, at 4:30 p.m. Eastern time, and will postpone the publication of its corresponding financial results." That same day, Marathon disclosed receipt of a letter from the U.S. Securities and Exchange Commission relating to accounting errors in the Company's previously issued financial statements. The Company advised investors that the "statements contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the previously issued unaudited condensed consolidated financial statements for the interim periods in 2022 and 2021 as contained in the Company's Quarterly Reports on Form 10-Q for the fiscal periods ended March 31, 2021 and 2022, June 30, 2021 and 2022 and September 30, 2021 and 2022 . . . should no longer be relied upon" and will be restated.

On this news, Marathon's stock price fell $0.59 per share, or 8.31%, to close at $6.51 per share on March 1, 2023.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP





View source version on accesswire.com:

https://www.accesswire.com/745805/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-on-Behalf-of-Investors-of-Marathon-Digital-Holdings-Inc--MARA



comtex tracking

COMTEX_427465442/2457/2023-03-24T16:30:27

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.